Gain-of-function mutations and increased EZH2 expression have been previously identified in patients with ovarian cancer, non-small-cell lung cancer, melanoma, breast cancer, prostate cancer, pancreatic cancer, and hematologic malignancies [29]. This evidence concerns the gene EZH2 and breast carcinoma.